Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Bhuvaneshwar Vaidya, Matthew Pangallo, Gregoire Ruffenach, Christine Marie Cunningham, Jeanette C. Perron, Srikanth Kolluru, Mansoureh Eghbali & Vivek Gupta. (2017) Advances in treatment of pulmonary arterial hypertension: patent review. Expert Opinion on Therapeutic Patents 27:8, pages 907-918.
Read now
Read now
Eric G Katz, Ronny BW Tan, Daniel Rittenberg & Wayne J Hellstrom. (2014) Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. Therapeutics and Clinical Risk Management 10, pages 701-711.
Read now
Read now
Min Chul Cho & Jae-Seung Paick. (2014) Udenafil for the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management 10, pages 341-354.
Read now
Read now
Roberto Bruzziches, Davide Francomano, Pietro Gareri, Andrea Lenzi & Antonio Aversa. (2013) An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opinion on Pharmacotherapy 14:10, pages 1333-1344.
Read now
Read now
Mohammad Amin Rezvanfar, Hamid Reza Rahimi & Mohammad Abdollahi. (2012) ADMET considerations for phosphodiesterase-5 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 8:10, pages 1231-1245.
Read now
Read now
Articles from other publishers (16)
Farnoosh Nik-Ahd & Alan W. Shindel. (2022) Pharmacotherapy for Erectile Dysfunction in 2021 and Beyond. Urologic Clinics of North America 49:2, pages 209-217.
Crossref
Crossref
Yurii Gurzhenko. (2021) A Comprehensive Approach in the Treatment of Erectile Dysfunction in Obesity Patients. Health of Man:4, pages 57-71.
Crossref
Crossref
Yurii Gurzhenko. (2021) Study of the Efficiency of Using Type 5 Phosphodiesterase Inhibitors in the Therapy of Ereсtile Dysfunction in Patients with Metabolic Syndrome. Health of Man:3, pages 58-69.
Crossref
Crossref
Jaesung Pyo. (2021) New Metabolites of Udenafil Identified through Liquid Chromatography– Quadrupole Time-of-flight Mass Spectrometry. Current Pharmaceutical Analysis 17:8, pages 1000-1007.
Crossref
Crossref
Hussein O. Ammar, Mina I. Tadros, Nahla M. Salama & Amira M. Ghoneim. (2020) Therapeutic Strategies for Erectile Dysfunction With Emphasis on Recent Approaches in Nanomedicine. IEEE Transactions on NanoBioscience 19:1, pages 11-24.
Crossref
Crossref
Ю. М. Гурженко. (2019) Physophydesterase Inhibitors of 5 Type and Erective Dysfunction. Health of Man:1, pages 64-74.
Crossref
Crossref
Hyang-Ki ChoiEon-Jeong ShimJihong ShonJin Ah JungJong-Lyul GhimJi-Hwa RyuKyun-Seop BaeJae-Gook Shin. (2016) Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine. Translational and Clinical Pharmacology 24:2, pages 90.
Crossref
Crossref
Zhi-wei Gao, Yun-ting Zhu, Ming-ming Yu, Bin Zan, Jia Liu, Yi-fan Zhang, Xiao-yan Chen, Xue-ning Li & Da-fang Zhong. (2015) Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharmacologica Sinica 36:12, pages 1528-1536.
Crossref
Crossref
Tsutomu Saji, Tomotaka Nakayama, Shinichi Takatsuki, Satoshi Ikehara, Hiromitsu Shimada, Kazuyuki Naoi, Mari Sato & Hiroyuki Matsuura. (2015) The Real World of Medical Treatment of Pulmonary Arterial Hypertension―Small Evidence, but Heavy Cornerstone―. Pediatric Cardiology and Cardiac Surgery 31:4, pages 157-183.
Crossref
Crossref
Zhe Li, Yinuo Wu, Ling-Jun Feng, Ruibo Wu & Hai-Bin Luo. (2014)
Ab Initio QM/MM Study Shows a Highly Dissociated S
N
2 Hydrolysis Mechanism for the cGMP-Specific Phosphodiesterase-5
. Journal of Chemical Theory and Computation 10:12, pages 5448-5457.
Crossref
Crossref
Rufael Chekol, Olivier Gheysens, Jan Cleynhens, Peter Pokreisz, Greet Vanhoof, Muneer Ahamed, Stefan Janssens, Alfons Verbruggen & Guy Bormans. (2014) Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5). Nuclear Medicine and Biology 41:2, pages 155-162.
Crossref
Crossref
Jeffrey A. Kyle, Dana A. Brown & Jerame K. Hill. (2013) Avanafil for Erectile Dysfunction. Annals of Pharmacotherapy 47:10, pages 1312-1320.
Crossref
Crossref
M. Ortaç, S. Çayan, M. K. Çalışkan, M. Ö. Yaman, T. M. Okutucu, M. B. Semerci, A. B. Altay, M. D. Balbay, M. F. Özcan & A. Kadıoğlu. (2013) Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double‐blind, placebo‐controlled study. Andrology 1:4, pages 549-555.
Crossref
Crossref
JinQiu Yuan, RenJie Zhang, ZuYao Yang, Jack Lee, YaLi Liu, JinHui Tian, XiWen Qin, ZhengJia Ren, Hong Ding, Qing Chen, Chen Mao & JinLing Tang. (2013) Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis. European Urology 63:5, pages 902-912.
Crossref
Crossref
Mehmet Guzeloglu, Koray Aykut, Gökhan Albayrak, Soner Atmaca, Suleyman Oktar, Alper Bagriyanik & Eyup Hazan. (2013) Effect of Tadalafil on Neointimal Hyperplasia in a Rabbit Carotid Artery Anastomosis Model. Annals of Thoracic and Cardiovascular Surgery 19:6, pages 468-474.
Crossref
Crossref
J H Lee, M R Chae, J K Park, J H Jeon & S W Lee. (2012) The effects of the combined use of a PDE5 inhibitor and medications for hypertension, lower urinary tract symptoms and dyslipidemia on corporal tissue tone. International Journal of Impotence Research 24:6, pages 221-227.
Crossref
Crossref